Reductions in Human Papillomavirus-Disease Resource Use and Costs with Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination: The FUTURE Study Economic Evaluation

Abstract Objective To examine the short-term impact of quadrivalent human papillomavirus (HPV) (types 6/11/16/18) recombinant vaccination upon HPV disease-related health-care resource utilization and costs among young women. Methods We analyzed data from a randomized clinical trial comparing quadriv...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2008-12, Vol.11 (7), p.1022-1032
Main Authors: Insinga, Ralph P., PhD, Dasbach, Erik J., PhD, Allen, Shannon E., PhD, Carides, George W., PhD, Myers, Evan R., MD, MPH
Format: Article
Language:English
Subjects:
Adolescent
cost
Costs and Cost Analysis
economics
Female
Follow-Up Studies
Health Care Costs
Health costs
Human papillomavirus
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Human papillomaviruses
Humans
Immunization
Internal Medicine
Papillomavirus Infections - economics
Papillomavirus Infections - prevention & control
Papillomavirus Infections - therapy
Papillomavirus Vaccines - economics
Papillomavirus Vaccines - therapeutic use
Short term
vaccine
Young Adult
Young women
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective To examine the short-term impact of quadrivalent human papillomavirus (HPV) (types 6/11/16/18) recombinant vaccination upon HPV disease-related health-care resource utilization and costs among young women. Methods We analyzed data from a randomized clinical trial comparing quadrivalent vaccination to placebo, among women (N = 7861) primarily 16 to 23 years of age at enrollment. HPV disease episodes, health-care resource utilization and costs associated with cervical, vaginal, and vulvar precancers, and anogenital warts were analyzed over a period of 2.5 years among women, regardless of baseline HPV status. Results Overall, there was a 25.9% ( P < 0.001) reduction in total HPV disease-related health-care costs among women receiving vaccine versus placebo (absolute reduction $3939 per 100 trial enrollees). We observed similar overall reductions in HPV-disease episodes and resource utilization. There was a statistically significant reduction in HPV 6/11-related disease episode costs of 65.1% ($1837 per 100), and a reduction of 51.4% ($1781 per 100) in HPV 16/18-related episode costs. Conclusions Quadrivalent HPV vaccination can reduce HPV disease events, resource use and costs when administered to a broad population of young women 16 to 23 years of age. Prevention of HPV types 6 and 11 yielded similar value in terms of HPV disease cost offsets, compared to protection against HPV 16 and 18, during the years initially after vaccination. Over the short-term, costs of vaccination exceed cost offsets associated with prevention of HPV disease; however, quadrivalent HPV vaccination has previously been shown to be cost-effective in the longer term, when fully accounting for health benefits and cost offsets.
ISSN:1098-3015
1524-4733
DOI:10.1111/j.1524-4733.2008.00342.x